- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT07779694
16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR/MSS Advanced Mid-to-Low Rectal Cancer
Neoadjuvant 16-Hour Fasting Combined With Serplulimab and CAPEOX for pMMR/MSS Locally Advanced Mid-to-Low Rectal Cancer: A Prospective, Single-Arm, Phase II Trial.
Although standard neoadjuvant chemoradiotherapy (nCRT) for locally advanced rectal cancer (LARC) effectively reduces local recurrence, radiotherapy-related toxicities and surgical complications severely impair patients' quality of life, making a radiotherapy-free strategy urgently needed. However, chemotherapy alone yields a pathological complete response (pCR) rate of only 6.6%-15%, which is far from satisfactory.
The pMMR/MSS subtype, accounting for 90% of rectal cancers, is "immune-cold" and shows almost no response to PD-1 monotherapy; nonetheless, chemotherapy can reshape the tumor immune microenvironment, and multiple studies have demonstrated that combining chemotherapy with PD-1 inhibitors (without radiotherapy) can elevate pCR rates to 26.8%-42.9%, yet further improvement remains desirable. A recent mechanistic study published in Cell Metabolism (2026) revealed that a single 16-hour fasting episode before treatment promotes isoleucine accumulation in the tumor microenvironment, which enhances CD8+T-cell cytotoxic function and reduces exhaustion through acetyl-CoA metabolism and epigenetic reprogramming, thereby significantly sensitizing PD-1 inhibitors-and this intervention is non-invasive, low-cost, and easily adoptable by patients.
Based on the above evidence, we hypothesize that the neoadjuvant triple-combination regimen of "16-hour fasting + chemotherapy + PD-1 inhibitor" (radiotherapy-free) in pMMR/MSS locally advanced mid-to-low rectal cancer may further increase pCR rates and tumor regression, offering a novel, highly effective, and low-toxicity therapeutic option for LARC patients.
A tanulmány áttekintése
Állapot
Körülmények
Beavatkozás / kezelés
Tanulmány típusa
Beiratkozás (Becsült)
Fázis
- 2. fázis
Kapcsolatok és helyek
Tanulmányi kapcsolat
- Név: feng Ke Ding
- Telefonszám: +86 13588425440
- E-mail: dingkefeng@zju.edu.cn
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
- Felnőtt
- Idősebb felnőtt
Egészséges önkénteseket fogad
Leírás
Inclusion Criteria:
- Willing and able to provide written informed consent.
- Male or female subjects ≧ 18 years ≦ 75 of age.
- Histological or cytological documentation of adenocarcinoma of the rectum.
- No previous any systemic anticancer therapy for rectal cancer disease.
- The primary rectal tumor is assessed as likely to be R0 resectable by a multidisciplinary colorectal cancer collaborative team, comprising at least 2 gastrointestinal surgeons and 1 radiologist.
- The lower margin of the tumor is less than 10cm from the anus verge.
- cT2N1-2M0, cT3N0-2M0, cT4N0-1M0 MSS with MRF(-) assessed by MRI.
- Primary tumor can be detected by CT or MRI.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Eligible tumor tissues were identified for MSI/MMR assays.
- Hepatitis B Surface Antigen (HBsAg) (-).
- If HBsAg (+) , HBV-DNA must be less than 2500 copies/mL or 500 IU/mL to be enrolled.
- Patients with HCV antibody (-) or HCV-RNA negative can be enrolled. Aspartate aminotransferase (AST) must be ≤ 3 x ULN for the lab. If HCV-RNA is positive, patients with both alanine aminotransferase (ALT) and aspartate aminotransferase (AST) performed ≤3×ULN could be enrolled. Patients infected with both hepatitis B virus and hepatitis C virus should be excluded (positive for HBsAg or HBcAb and positive for HCV antibodies).
Exclusion Criteria:
- Patients with recurrent rectal cancer or a history of pelvic radiotherapy.
- Patients with a history of inflammatory bowel disease.
- Patients with acquired immunodeficiency syndrome (AIDS-related illnesses) or known human immunodeficiency virus (HIV) disease (HIV1 antibody, HIV2 antibody, HTLV1 antibody positive) should be excluded.
- Patients who are preparing for or have previously received an organ or bone marrow transplant.
- History of myocardial infarction, poorly controlled arrhythmias (including QTc interval ≥470 ms in women) in the 6 months prior to enrollment (QTc interval calculated by Fridericia formula).
- According to New York College of Cardiology (NYHA) standards for Grade III-IV cardiac insufficiency or cardiac color ultrasound: left ventricular ejection fraction (LVEF) <50%.Poor hypertension control (systolic blood pressure ≥150 mmHg and/or diastolic blood pressure ≥100 mmHg), a past hypertensive crisis or hypertensive encephalopathy.
- Poor hypertension control (systolic blood pressure ≥150 mmHg and/or diastolic blood pressure ≥100 mmHg), a past hypertensive crisis or hypertensive encephalopathy.
- Patients had undergone major surgery within 28 days prior to enrollment. Patients with tumor biopsy or lymph node dissection biopsy were admitted. Patients undergoing enterostomy due to intestinal obstruction were admitted.
- The patients had previously been treated with other antibodies/drugs that target immune checkpoints, such as PD-1, PD-L1, and cytotoxic T lymphocyte-associated Antigen 4 (CTLA-4).
- Patients are participating in other clinical studies, or plan to start this study treatment less than 14 days from the end of the previous clinical study.
- Uncontrolled tumor-related pain.
- A known history of severe allergy to any monoclonal antibody.
- Known to be allergic or intolerance to any oxaliplatin and capecitabine ingredients.
- Pregnant or lactating women.
- The investigators determined that the patient had other factors that might have led to the early termination of the study.
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: N/A
- Beavatkozó modell: Egyetlen csoportos hozzárendelés
- Maszkolás: Nincs (Open Label)
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Kísérleti: 16-Hour Fasting + Serplulimab + CAPEOX
Patients enrolled in the study are required to fast for 16 hours prior to the administration of serplulimab in combination with CAPEOX. Serplulimab: 300 mg, IV, d1, q3w. CAPEOX regimen: Oxaliplatin(130mg/m2) on day 1 of each cycle and Capecitabine, 1000mg/m2, PO, BID, day1-14, q3w. Treatment repeats every 3 weeks for 4 cycles followed by surgery (total mesorectal excision, TME). |
Patients begin fasting at 20:00 on the day prior to immunotherapy (only plain water is allowed) and continue until 10:00 the next morning, when serplulimab is administered.
Fasting is maintained until 12:00 noon, after which normal diet may be resumed.
Serplulimab is an innovative monoclonal antibody targeting PD-1, developed by Shanghai Henlius Biotech, Inc. 300 mg, IV, d1, q3w. CAPEOX regimen: Oxaliplatin(130mg/m2) on day 1 of each cycle and Capecitabine, 1000mg/m2, PO, BID, day1-14, q3w. 4 cycles |
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Pathological complete response rates
Időkeret: 10 days after surgery
|
Proportion of participants achieving pathological complete response (pCR) after neoadjuvant therapy.
|
10 days after surgery
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Rate of clinical complete response rate(cCR)
Időkeret: 1 year
|
Proportion of participants achieving clinical complete response (cCR) after neoadjuvant therapy.
|
1 year
|
|
R0 resection rates
Időkeret: 10 days after surgery
|
Proportion of patients achieved a complete resection with negative margin
|
10 days after surgery
|
|
Disease Free Survival
Időkeret: 3 years
|
Defined as the interval from enrollment to locoregional or metastatic recurrence or the appearance or a secondary colorectal cancer or death, whichever occurs first
|
3 years
|
|
Event free survival
Időkeret: 3 years
|
Defined as the time from enrollment to the first occurrence of any of the following events: tumor disease progression on imaging as assessed by RECIST 1.1; tumor recurrence, including local recurrence or distant recurrence, as assessed on imaging or tissue biopsy transfer; death from any cause.
|
3 years
|
|
Overall survival (OS)
Időkeret: 3 years
|
Defined as the time between the date of enrollment and death from any cause.
|
3 years
|
|
Treatment-related adverse events
Időkeret: 1 year
|
Assessed by evaluation of treatment-related adverse events.
|
1 year
|
|
Single-Cell RNA Sequencing (scRNA-seq) of Tumor Microenvironment
Időkeret: 1 year
|
Use single cell sequence to describe changes in the microenvironment of rectal cancer before and after treatment.
|
1 year
|
|
Spatial Transcriptomics Profiling of Tumor and Stroma
Időkeret: 1 year
|
Explore spatial organization of gene expression within the tumor microenvironment and its association with treatment response using spatial transcriptomics.
|
1 year
|
Együttműködők és nyomozók
Szponzor
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Becsült)
Elsődleges befejezés (Becsült)
A tanulmány befejezése (Becsült)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
Kulcsszavak
További vonatkozó MeSH feltételek
- Neoplazmák webhelyenként
- Neoplazmák
- Bélbetegségek
- Gasztrointesztinális neoplazmák
- Emésztőrendszeri neoplazmák
- Emésztőrendszeri betegségek
- Emésztőrendszeri betegségek
- Kolorektális neoplazmák
- Bél neoplazmák
- Rektális betegségek
- Viselkedés
- Táplálkozási viselkedés
- Böjtölés
- Rektális neoplazmák
- Böjt időszak
- Terápiás kezelés
- Gyógyszeres kezelés
Egyéb vizsgálati azonosító számok
- SCAR2
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .